Hopkins' Stem Cell Selection Patents Upheld

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 8
Volume 6
Issue 8

WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay Johns Hopkins University, Becton Dickinson & Company, and Baxter Healthcare Corp. $7 million in damages for its willful infringement of patents involving stem cell selection technology.

WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay JohnsHopkins University, Becton Dickinson & Company, and Baxter HealthcareCorp. $7 million in damages for its willful infringement of patents involvingstem cell selection technology.

The judge also ordered an injunction against CellPro's patent-infringingstem cell selection system (Ceprate Stem Cell Concentration System andCeprate LC34 Laboratory Cell Separation System). This injunction will bedelayed in this country until an alternative system, licensed under thepatents, is approved by the FDA.

Johns Hopkins and its licensees requested the delay to ensure that transplantpatients have uninterrupted access to stem cell selection technology. Baxter'sIsolex 300 Magnetic Cell Separator System, already in widespread use inclinical trials, is currently under FDA review.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
6371178759112
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Data show increasing use of proton therapy overall but widening gaps in populations who have access to this treatment, says Curtiland Deville Jr., MD.
Related Content